“Chimpanzee Adenovirus Vector Ebola Vaccine.”. N Engl J Med 376 (10). N Engl J Med: 928-938. doi:10.1056/NEJMoa1410863.
. 2017. “Use Of Chad3-Ebo-Z Ebola Virus Vaccine In Malian And Us Adults, And Boosting Of Malian Adults With Mva-Bn-Filo: A Phase 1, Single-Blind, Randomised Trial, A Phase 1B, Open-Label And Double-Blind, Dose-Escalation Trial, And A Nested, Randomised, Double-Bli”. Lancet Infect Dis 16 (1). Lancet Infect Dis: 31-42. doi:10.1016/S1473-3099(15)00362-X.
. 2016. “Safety And Immunogenicity Of Ebola Virus And Marburg Virus Glycoprotein Dna Vaccines Assessed Separately And Concomitantly In Healthy Ugandan Adults: A Phase 1B, Randomised, Double-Blind, Placebo-Controlled Clinical Trial.”. Lancet 385 (9977). Lancet: 1545-54. doi:10.1016/S0140-6736(14)62385-0.
. 2015. “Homologous Boosting With Adenoviral Serotype 5 Hiv Vaccine (Rad5) Vector Can Boost Antibody Responses Despite Preexisting Vector-Specific Immunity In A Randomized Phase I Clinical Trial.”. Plos One 9 (9). Plos One: e106240. doi:10.1371/journal.pone.0106240.
. 2014. “Phase I Randomized Clinical Trial Of Vrc Dna And Rad5 Hiv-1 Vaccine Delivery By Intramuscular (I.m.), Subcutaneous (S.c.) And Intradermal (I.d.) Administration (Vrc 011).”. Plos One 9 (3). Plos One: e91366. doi:10.1371/journal.pone.0091366.
. 2014. “Dna Vaccine Delivered By A Needle-Free Injection Device Improves Potency Of Priming For Antibody And Cd8+ T-Cell Responses After Rad5 Boost In A Randomized Clinical Trial.”. Plos One 8 (4). Plos One: e59340. doi:10.1371/journal.pone.0059340.
. 2013. “Protection Against Malaria By Intravenous Immunization With A Nonreplicating Sporozoite Vaccine.”. Science 341 (6152). Science: 1359-65. doi:10.1126/science.1241800.
. 2013. “Therapeutic Vaccination Expands And Improves The Function Of The Hiv-Specific Memory T-Cell Repertoire.”. J Infect Dis 207 (12). J Infect Dis: 1829-40. doi:10.1093/infdis/jit098.
. 2013. “Priming Immunization With Dna Augments Immunogenicity Of Recombinant Adenoviral Vectors For Both Hiv-1 Specific Antibody And T-Cell Responses.”. Plos One 5 (2). Plos One: e9015. doi:10.1371/journal.pone.0009015.
. 2010. “A Sars Dna Vaccine Induces Neutralizing Antibody And Cellular Immune Responses In Healthy Adults In A Phase I Clinical Trial.”. Vaccine 26 (50). Vaccine: 6338-43. doi:10.1016/j.vaccine.2008.09.026.
. 2008. “Phase I Clinical Evaluation Of A Six-Plasmid Multiclade Hiv-1 Dna Candidate Vaccine.”. Vaccine 25 (20). Vaccine: 4085-92. doi:10.1016/j.vaccine.2007.02.050.
. 2007. “Safety, Immunogenicity And Efficacy Of Modified Vaccinia Ankara (Mva) Against Dryvax Challenge In Vaccinia-Naïve And Vaccinia-Immune Individuals.”. Vaccine 25 (8). Vaccine: 1513-25. doi:10.1016/j.vaccine.2006.10.047.
. 2007. “Phase 1 Safety And Immunogenicity Evaluation Of A Multiclade Hiv-1 Candidate Vaccine Delivered By A Replication-Defective Recombinant Adenovirus Vector.”. J Infect Dis 194 (12). J Infect Dis: 1638-49. doi:10.1086/509258.
. 2006. “Phase 1 Safety And Immunogenicity Evaluation Of A Multiclade Hiv-1 Dna Candidate Vaccine.”. J Infect Dis 194 (12). J Infect Dis: 1650-60. doi:10.1086/509259.
. 2006.